

KEYWORD INDEX

2019 novel coronavirus (SARS-CoV-2), 944

autoimmune chronic prostatitis, 712
autophagy, 429, 911

Chidamide, 1004

children, 281

Cholangiocarcinoma cells, 429

cisplatin, 732

clinical pathological characteristics, 515

c-Met, 81, 196

c-Myc, 423, 615

colitis, 705

colony formation, 494

commercially pure titanium (cp Ti), 212

computed tomography, 129

consumption, 834

coronavirus disease 2019, 389

COVID-19, 296, 393

COX-2, 328

C-reactive protein to albumin ratio, 54

critical care, 841

Crk, 265

current density, 543

CXCL2, 885

Cyclophilin A, 122

cytokine, 441

A

ABL2, 592

abnormal spindle-like microcephaly associated, 1021

action research, 371

acute exacerbations of chronic obstructive pulmonary disease, 107

acute lung injury, 929

acute pneumonia, 607

adipose tissue-derived mesenchymal stem cell (ADSC), 405

ADR, 98

age determination by skeleton, 937

air, 129

airway remodeling, 508

airway smooth muscle cell (ASMC), 869

airway smooth muscle cells, 508

AKI, 817

AKT, 250, 417

AKT/mTOR, 405

alcoholic hepatitis, 904

allergic rhinitis, 622

allogeneic hematopoietic stem cell transplantation, 825

alternative splicing, 13, 171

ankylosing spondylitis, 441

ankyrin, 552

anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy, 650

anti-apoptosis, 732

antibiotics, 160

antioxidant capacity, 43

antiretroviral therapy, 450

antithyroid drug, 281

apoptosis, 429, 607, 630, 965, 1004

aqueous extract, 43

artificial intelligence, 937

Asian, 1030

asthma, 62, 508

atmospheric pollution, 834

atopic dermatitis, 186

B

Bcl-2, 1004

BDNF, 27

bending, 212

benign liver nodule, 460

beta-catenin, 895

biomarkers, 122

bladder cancer, 1021

BMSCs, 35

bonding strength, 212

bone age, 937

bone marrow microenvironment, 825

breast cancer, 250, 640

bubble continuous positive airway pressure (bCPAP), 371

C

CAD, 920

carcinogenesis, 178

carcinoma, 196

β-catenin, 405

CCND1, 775

CD274, 581

CD4 T-lymphocyte, 450

CDK14, 808

cell apoptosis, 998

cell culture, 460

cell growth, 399, 417, 423, 501, 615, 878

cell invasion, 494

cell motility, 895

cell proliferation, 494

cell survival, 983

cell viability, 336

cerebral infarction, 122

cerebral ischemia reperfusion injury, 741

cervical cancer, 328, 336, 450, 965

cervical carcinoma, 501, 878

change, 371

D

DAA, 920

Dendrobium officinale, 43

dengue virus, 911

dental education, 850

desfurane, 834

desmoglein-2, 336

DEX, 35

dexmedetomidine, 721

differential diagnosis, 460

differentiated thyroid carcinoma (DTC), 236

DJ-1, 630

DKK1, 35

drug resistance, 983

dynamic changes, 107

E

E2F1, 692

EEG, 543

- efficiency, 834
 ELAVL1, 965
 ellagic acid, 699
 EMI2 (FBXO43), 640
 EMT, 265
 endometrial cancer, 13, 171
 endoscopic retrograde
 cholangiopancreatography, 129
 energy metabolism, 523
 epidemiology, 450
 epithelial ovarian cancer, 799
 esophageal cancer, 54, 318
 esophageal squamous cell carcinoma, 699
 exercise, 62
 exosome, 363
 extracellular matrix deposition, 508
- F**
- FAM3C, 318
 fecal microbiota transplantation, 160
 fibroblast-like synoviocytes, 20
 fine needle lymph node aspiration for
 thyroglobulin (LN-FNA-Tg), 236
 fine-needle aspiration, 750
 FKBP10, 311
 fluid, 129
 folic acid, 344
 follicular thyroid carcinoma (FTC), 236
 furazolidone, 998
- G**
- Gambogenic acid, 344
 gas explosion, 929
 gastric cancer, 178, 244, 515, 1014
 ghrelin, 405
 ginsenoside Rk1, 732
 glucose uptake, 911
 glycolysis, 911
 GP73, 793
 Graves' disease, 281
 growth curve, 937
 gut-lung, 107
- H**
- HCC, 615
 HCV, 920
 HDAC, 1004
- HDAC8, 904
 heat shock protein, 186
 HEK-293, 732
 hematopoietic reconstruction, 825
 hemodialysis, 393
 hepatic stellate cells, 990
 Hepatocellular, 196
 hepatocellular carcinoma, 98, 423, 460,
 750, 793
 HepG2, 98
 hereditary spherocytosis, 552
 HIV, 450
 HLA-B27, 441
 HMGB1, 483, 622
 HN1, 196
 hospital employee, 944
 HOTTIP, 973
 hsa-miR-570-3p, 581
 hypercholesterolemia, 1030
 hypoxic-ischemic brain damage, 43
- I**
- IKK β , 998
 IL6R, 20
 immune-mediated necrotizing
 myopathy, 650
 immunoglobulin, 650
 infection control, 296, 393
 infectious diseases, 944
 inflammation, 257, 523, 607, 705,
 721, 904
 inflammatory bowel disease, 257
 inflammatory injury, 20
 intraoperative neural monitoring, 230
 invasion, 81, 311, 318, 793, 799, 885
 IRF1, 799
 iron overload, 825
 irritable bowel syndrome, 160
 ischemia/reperfusion, 599
- J**
- JAK2/STAT3, 328, 673
 JAK/STAT3 signaling pathway, 257
 Japan, 135
- K**
- KIF3B, 515
- L**
- Let-7b, 775
 lidocaine, 274, 630
 lipid, 920
 lipopolysaccharides, 607
 liver cancer, 399
 lncRNA TUG1, 354
 local recurrence, 152
 locally advanced rectal cancer, 152
 loganin, 257
 LORETA, 543
 low-flow anesthesia, 834
 L-PRF, 305
 L-PRP, 305
 LSCC, 983
 lymph node metastasis (LNM), 236
- M**
- Macrophages, 692
 magnetic resonance imaging, 650
 MALAT1, 13
 MAPK, 336
 MAPK1 proliferation, 318
 MC3T3-E1 cells, 673
 mechanical ventilation, 841
 mesenchymal stem cell, 363
 meta-analysis, 54
 metastasis, 265, 483, 592, 640
 METTL3, 895
 microbiome, 107
 microbiota, 160
 microRNA, 171, 786
 MicroRNA-129-5p, 483
 MicroRNA-155, 712
 MicroRNA-216b, 423
 microRNA-301b, 878
 microRNA-425-5p, 250
 microRNA-590-3p, 501
 microRNA-620 (miR-620), 869
 migraine, 543
 migration, 311, 885
 miR-129-5p, 599
 miR-135b, 673
 miR-141-3p, 622
 miR-15a, 27
 miR-194-5p, 265
 miR-212, 81
 miR-22, 20
 miR-291a-3p, 35
 miR-324-5p, 965

- miR-326, 508
 miR-34a, 1004
 miR-34b-3p, 817
 MiR-370, 741
 miR-373, 429
 miR-431-5p, 808
 miR-451a, 494, 904
 miR-495, 607
 miR-499-5p, 244
 miR-559, 793
 miR-574-3p, 318
 miR-615-3p, 973
 miR-744-5p, 799
 miR-922, 178
 miRNA, 274, 592
 miRNA profile, 114
 miRNA-532-5p, 885
 miRNA-mRNA-pathway network, 114
 missed abortion, 114
 mitochondrial unfolded protein response, 89
 MUC16, 328
 myocardial injury, 599
- N**
- Nasal epithelial cell, 622
 nasopharyngeal carcinoma, 895
 needle aspiration, 460
 neoadjuvant chemoradiotherapy, 152
 neonatal nursing staff, 371
 nephrotoxicity, 732
 neural differentiation, 405
 neuromuscular blocking agents, 230
 neuron, 27
 neuronal apoptosis, 43
 new psychoactive substance (NPS)
 legislation, 135
 next-generation sequencing, 114
 NF-κB, 399, 705, 712, 786, 817, 998
 NF-κB pathway, 354
 NF-κB signaling pathway, 20
 nitric oxide (NO), 535
 noble gases, 212
 noncognitive performance, 850
 nonionic surfactant vesicles, 344
 non-small cell lung cancer, 417
 nonsurgical treatment, 7
 novel coronavirus, 296
 Nrf2/ARE signal pathway, 741
 nuclear factor erythroid 2 related factor
 (Nrf2), 630
 Numb, 171
- O**
- Obstructive sleep apnea, 7
 OSCC, 483
 OSCE, 850
 osteoblast differentiation, 673, 775
 osteogenic differentiation, 35
 osteoporosis, 775
 osteosarcoma, 885
 OTUB2, 399
 outcome, 750
 ovarian cancer, 973
 oxidative stress, 89, 630
- P**
- Papillary thyroid cancer, 808
 papillary thyroid carcinoma (PTC), 236
 Paris saponin VII, 98
 Parkinson's disease, 786
 patient-child relationship, 62
 PCSK9, 705
 PDCD4, 244
 PDTC, 354
 perforation, 129
 phosphatase and tensin homolog
 (PTEN), 869
 PI3K, 250
 PI3K/AKT pathway, 27, 990
 PI3K/AKT/MAPK, 98
 PI3K/AKT/mTOR, 581
 pituitary adenoma, 81
 plasmacytoid dendritic cells, 441
 plasminogen activator inhibitor-1, 929
 polarization, 692
 poor graft function, 825
 porcelain fused to metal (PFM), 212
 postoperative cognitive dysfunction, 721
 PPAR-γ, 692
 P-PRF, 305
 P-PRP, 305
 primary culture, 750
 probiotics, 160
 prognosis, 54, 196, 311, 1014, 1021
 progression, 328, 808
 proliferation, 515, 793, 799, 1004,
 1021
 prostate cancer, 494
 protein kinase B (AKT), 869
 PSMB8, 494
 PTEN, 250, 417
 pulse pressure, 122
- Q**
- QTc prolongation, 1030
- R**
- Radiation therapy, 965
 radiation-induced liver injury, 990
 RBM10, 13
 recurrence, 750
 recurrent laryngeal nerve, 230
 recurrent pregnancy loss, 363
 regenerative therapy, 305
 remission, 281
 renal cell carcinoma, 592
 renin-angiotensin system), 389
 resveratrol, 535
 rheumatoid arthritis, 20, 523
 rigidity, 1030
 rituximab, 650
 RNF38, 878
 RNF6, 699
 ROCK1, 607
- S**
- SARS-CoV-2, 296
 SBF2-AS1, 808
 schizophrenia, 1030
 senescent fibroblasts, 89
 sepsis, 817
 SHP-1, 699
 SIRT1, 535
 SIRT6, 741
 skin barrier, 186
 skin inflammation, 186
 SLC4A1, 552
 SLE, 354
 small cell lung cancer, 998
 SMARCE1, 973
 SNP, 206
 social persuasion, 62
 SOCS2, 599
 South Korea, 135
 SOX2, 983
 spectrin, 552
 spectrum edge frequency, 543
 splenectomy, 552
 Stat-3, 244, 699
 state-trait anxiety, 850
 STIM1-Orai1-dependent SOCE, 89

- stomach adenocarcinoma, 311
stress, 944
stroke recurrence, 122
suppressors of cytokine signaling 1, 178
surgery, 152
surgical treatment, 7
SVR, 920
systematic review, 206
- T**
Tai-Chi-Chuan, 62
Taiwan, 135, 296
Tankyrase, 895
target, 399, 501, 615
targeted delivery, 344
TfR2, 1014
TGF- β 1, 990
therapeutic target, 515
thermal injury, 274
thymic stromal lymphopoietin, 186
thyroid surgery, 230
- thyroid-stimulating hormone receptor
antibodies, 281
tissue factor, 929
tissue factor pathway inhibitor, 929
TLR4, 705, 712
TLR4/NF- κ B signaling pathway, 257
TNFSF14, 508
Toll-like receptors, 206
transforming growth factor- β 1 (TGF- β 1), 869
translocation, 786
TRIM26, 417
- U**
UBE2N, 501
UBL4A, 817
ULK1, 429
unfolded protein response, 441
urinary tract infection, 206
USP13, 615
- thyroid-stimulating hormone receptor
antibodies, 281
tissue factor, 929
tissue factor pathway inhibitor, 929
TLR4, 705, 712
TLR4/NF- κ B signaling pathway, 257
TNFSF14, 508
Toll-like receptors, 206
transforming growth factor- β 1 (TGF- β 1), 869
translocation, 786
TRIM26, 417
- V**
VEGFA, 13
 δ -Viniferin, 535
- W**
Weaning, 841
Wnt/ β -catenin signaling pathway, 775
wound healing, 274, 692
WT, 265
- X**
Xanthone, 523